Asthma drug delivery manufacturer InfaMed, a subsidiary of Australian Stock Exchange-listed Visiomed, has appointed a Singaporean distributor of its patented paediatric asthma device, the Funhaler.
Asthma drug delivery manufacturer InfaMed, a subsidiary of Australian Stock Exchange-listed Visiomed, has appointed a Singaporean distributor of its patented paediatric asthma device, the Funhaler. E-xclusif Medical Supply, a medical product distributor specialising in nebulisers and respiratory care products, will distribute the Funhaler product to pharmacies, physician clinics and hospitals, initially into Singapore and subsequently into the rest of the Asia-Pacific market. Visiomed chief executive William Dolphin said the appointment of E-xclusif represented a major step for the company and its plans for the global commercialisation of the Funhaler. "Singapore is a gateway to the very large Asia-Pacific region. The commitment of E-xclusif to significant minimum purchases underscores their confidence in the product and the attractiveness of the Funhaler to this market", Mr Dolphin said. The Funhaler incorporates user feedback to assist in developing and maintaining proper inhalation technique. The product was designed to improve children's medication habits.
Subscribe today for award-winning, unbiased and trusted journalism